Citations

Clear

13603 citation(s) found for "_, _".

Peri-Implant Enhancement of the Breast: Imaging Features, Significance, and Management Strategies
Maimone, Santo , Srivastava, Shweta, Ho, Olivia A. , Robinson, Kristin A. , Morozov, Andrey P, Letter, Haley , Leon, Amie , Rinker, Brian, Ho, Olivia S, Letter, Haley P, Maimone, Santo , Srivastava, Shweta

Mayo Clinic

Journal of Breast Imaging | December 21, 2024 | Volume: 7 | Issue: 3 | Pages: 301-310

10.1093/jbi/wbae084 | PMID 39707944 Get It

Abstract Objective Peri-implant enhancement can be seen on contrast-enhanced breast MRI, but its association with malignancy has not been described, leading to considerable variability in assessment and recommendations by radiologists. This study evaluated imaging features, management, and outcomes of implant-related enhancement. Methods This multisite IRB-approved retrospective review queried all breast MRI reports for keywords describing peri-implant enhancement, fluid, and/or masses (plus synonymous descriptions) and implant-associated malignancies, with subsequent imaging and chart review. Peri-implant enhancement and implant features were characterized. Assessments and outcomes were evaluated via clinical and imaging follow-up, aspiration/biopsy, and/or capsulectomy to evaluate for association of peri-implant enhancement with implant-related malignancy. Results A total of 100 patients had peri-implant enhancement. Uniform thin peripheral enhancement was most common (79/100, 79%). Capsulectomy was performed in 31/100 (31%), with benign capsular fibrosis/inflammation discovered in 26/31 (83.9%). Breast implant–associated anaplastic large cell lymphoma was present in 2/100 (2%), both with textured implants, while 98/100 (98%) had no implant-related malignancy. MRI recommendations varied: resume routine imaging (26/100, 26%), clinical management (18/100, 18%), follow-up MRI (17/100, 17%), MRI-directed US (17/100, 17%), aspiration/biopsy (11/100, 11%), and surgical consultation (10/100, 10%). Conclusion Peri-implant enhancement is a nonspecific imaging finding with a low malignant association, especially when seen in isolation (no associated effusion, mass, or adenopathy). Implant surface texture should be considered in management recommendations; diagnostic capsulectomy is not recommended in patients with smooth implants. Additional studies are encouraged to validate nonoperative management recommendations.
Utilization of Interval Throwing Programs: Analysis of Athletic Trainer, Physical Therapist, and Physician Perspectives
Sciascia, Aaron , Grantham, W. Jeffrey , Stone, Austin V. , Tremble, Corey, Uhl, Tim L. , Kibler, W. Ben, Uhl, Tim , Camp, Christopher L. , Sciascia, Aaron D. , Tremble, Corey S , Kibler, W. Ben

Mayo Clinic

Journal of Sport Rehabilitation | December 21, 2024 | Volume: 34 | Issue: 5 | Pages: 523-535

10.1123/jsr.2024-0171 | PMID 39708791 Get It

Context : A common component within rehabilitation recommendations for baseball pitchers is employment of an interval throwing program. However, there is a lack of a consistent set of advocated guidelines for program content and implementation for athletes at the professional and collegiate levels. Design : Cross-sectional study. Methods : A survey was developed to obtain clinician views regarding the composition and implementation of interval throwing programs for baseball pitchers. The survey was divided into demographic information and sections on criteria to begin throwing programs, frequency of throwing, soreness management, warm-up components, program components and regulation of a program, and criteria to achieve permitting live throwing. Clinicians including physicians, physical therapists, and certified athletic trainers who evaluate and treat musculoskeletal injuries among baseball pitchers at the professional-level and/or collegiate-level clinician received the survey. Responses were tabulated and compared between the professional-level clinician and collegiate-level clinician groups using chi-square analyses with statistical significance set at P ≤ .05. Results : The survey was completed by 166 clinicians (collegiate level = 81, professional-level clinician = 85). There were no statistical differences between groups for allowing warm-up throws, program regulation, maximum distance allowed, managing soreness, or criteria to achieve before permitting live throwing. Between-group differences included criteria to begin a program (≤.03), warm-up distance ( P ≤ .02), nonthrowing warm-up methods ( P ≤ .04), non-warm-up distance ( P ≤ .01), using ratings of perceived exertion ( P < .01), throwing frequency ( P < .01), and program components ( P ≤ .04). Conclusions : Responses appear to mirror interval throwing program designs previously reported in the literature but there are modifications and additions utilized by clinicians at different playing levels.
Executive Summary of State-of-the-Art Review: Modern Approach to Nocardiosis—Diagnosis, Management, and Uncertainties
Yetmar, Zachary A. , Marty, Paige K. , Clement, Josh , Miranda, Cyndee , Wengenack, Nancy L. , Beam, Elena , Yetmar, Zachary A , Beam, Elena

Mayo Clinic

Clinical Infectious Diseases | December 20, 2024 | Volume: 80 | Issue: 4 | Pages: 701-702

10.1093/cid/ciae644 | PMID 40305687 Get It

State-of-the-Art Review: Modern Approach to Nocardiosis—Diagnosis, Management, and Uncertainties
Yetmar, Zachary A. , Marty, Paige K. , Clement, Josh , Miranda, Cyndee , Wengenack, Nancy L. , Beam, Elena , Yetmar, Zachary A , Beam, Elena

Mayo Clinic

Clinical Infectious Diseases | December 20, 2024 | Volume: 80 | Issue: 4 | Pages: e53-e64

10.1093/cid/ciae643 | PMID 40305688 Get It

Abstract Nocardiosis is an uncommon yet potentially devastating infection. Nocardia tends to affect individuals with chronic lung disease or immunocompromising conditions, 2 groups increasing in number. Incidence of nocardiosis is likely to increase as well, and it is vital to have an approach to this complex disease. Here, we aim to review the presentation, diagnosis, and management of Nocardia in the modern era. We will also highlight areas of uncertainty in our understanding of nocardiosis and propose a general approach to nocardiosis therapy, accounting for response and tolerance of Nocardia treatment.
The Fifth Annual Symposium of the Midwest Aging Consortium
Reader, Brenda F. , Rosas, Lorena , Knopf, Bailey A. , Liu, Yang , Bhat, Ajay , Carey, Anna , Elliehausen, Christian J., Englund, Davis A. , Hamilton, H., Johnston, Matthew , Kang, Ping, Konopka, Adam R. , Lepola, Noah, Schafer, Marissa , Singer, Benjamin D. , Song, Min‐Ae , Wei, Wei , Zhang, Lei , Zhang, Lei , Lamming, Dudley W. , Knopf, Bailey Anna , Bhat, Ajay , Carey, Anna , Konopka, Adam R , Presley, Carolyn J , Zhang, Lei , Zhang, Lei , Anderson, Rozalyn M , Bai, Hua , Lamming, Dudley W , Schafer, Marissa J , Englund, Davis A. , Alzate‐Correa, Diego , Cuervo, Ana M , Dayal, Sanjana , Demarco, Rafael Sênos , Kang, Ping, Lepola, Noah , Presley, Carolyn J. , Serrano, Joan , Stanford, Kristin I. , Taylor, Jackson R. , Yeh, Chung‐Yang , Anderson, Rozalyn M. , Robbins, Paul D. , Mihaylova, Maria M. , Rojas, Mauricio M. , Mora, Ana Lucia

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | December 20, 2024 | Volume: 80 | Issue: 2 | Pages: No page available

10.1093/gerona/glae296 | PMID 39704343 Get It

Abstract As the healthcare burden caused by an increasingly aging population rapidly rises, a pressing need exists for innovative geroscience research that can elucidate aging mechanisms and precipitate the development of therapeutic interventions to support healthy aging. The Fifth Annual Midwest Aging Consortium Aging Research symposium, held from April 28 to 30, 2024, was hosted by The Ohio State University in Columbus, Ohio, and featured presentations from investigators across the Midwestern United States. This report summarizes the research presented at the symposium, whose topics included cellular senescence and the aging brain, metabolism and metabolic interventions, nutrition, redox mechanisms and biomarkers, and stress mechanisms. Abstract presentations and short talks highlighted early-stage and young investigators, whereas 2 keynote presentations anchored the symposium. Overall, this symposium showed the robustness of aging research in the Midwest and underscored the advantages of a collaborative approach to geroscience research.
Treatment of Established Chemotherapy-Induced Neuropathy with N-Palmitoylethanolamide: A Randomized, Double-Blind Phase II Pilot Study
Davis, Mellar P. , Ulrich, Angela , Gudena, Vinay, Ruddy, Kathryn J. , D’Andre, Stacy D. , Giridhar, Karthik V. , Vasireddy, Vamsi K., Agarwal, Rajiv , Azzouqa, Abdel‐Ghani, Novotny, Paul, McCue, Shaylene , Bauer, Brent A. , Loprinzi, Charles L. , Giridhar, Karthik V , Agarwal, Rajiv , Bauer, Brent A , Loprinzi, Charles , Ulrich, Angela , Segal, Rebecca A.

Mayo Clinic

Cancers | December 20, 2024 | Volume: 16 | Issue: 24 | Pages: 4244

10.3390/cancers16244244 | PMID 39766143 Get It

Background: Chemotherapy-induced peripheral neuropathy (CIPN) from oxaliplatin and taxane drugs is a bothersome toxicity. Palmitoylethanolamide (PEA) has been reported to improve myelinated nerve fiber function in patients experiencing painful CIPN. We conducted a double-blind, placebo-controlled, randomized trial of PEA in patients with established CIPN. Methods: Eligible patients were adults who had pain, numbness, tingling, or other symptoms of CIPN for at least three months following completion of paclitaxel, oxaliplatin, or cisplatin-based chemotherapy. Study patients were randomized to one of the two treatment groups (PEA versus placebo, both administered either once or twice daily). The CIPN20 questionnaire was assessed weekly. Results: A total of 17 males and 71 females participated in the study; most had neuropathy from paclitaxel. Most (85%) finished 8 weeks of treatment. There was no suggestion that either of the PEA arms did any better than the combined placebo arms. There was no signal of significant toxicity differences between the three study arms. Quality of life outcome measures were similar between the study arms, as were cognitive function evaluations. Discussion: PEA failed to improve established CIPN. Future trials might explore whether PEA may be effective in preventing CIPN or cognitive changes based on data that suggest it may be helpful in this situation. Conclusions: PEA failed to improve established chemotherapy-induced neuropathy.
The role of social, economic, and medical marginalization in cancer clinical trial participation inequities: A systematic review
Hanvey, Grace Ann , Johnson, Hannah , Cartagena, Gabriel, Dede, Duane E., Krieger, Janice L. , Ross, Kathryn M. , Johnson, Hannah, Dede, Duane E., Pereira, Deidre Byrnes

Mayo Clinic

Journal of Clinical and Translational Science | December 20, 2024 | Volume: 9 | Issue: 1 | Pages: No page available

10.1017/cts.2024.677 | PMID 40052046 Get It

Abstract Extant literature reveals how patients of marginalized social identities, socioeconomic status (SES), and medical experiences – especially patients of color and older adults – are underrepresented in cancer clinical trials (CCTs). Emerging evidence increasingly indicates CCT underrepresentation among patients of lower SES or rural origin, sexual and gender minorities, and patients with comorbid disability. This review applies an intersectional perspective to characterizing CCT representativeness across race and ethnicity, age, sexual and gender identity, SES, and disability. Four databases were systematically queried for articles addressing CCT participation inequities across these marginalizing indicators, using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. One hundred one articles were included in a qualitative evaluation of CCT representativeness within each target population in the context of their intersectional impacts on participation. Findings corroborate strong evidence of CCT underrepresentation among patients of color, older age, lower SES, rural origin, and comorbid disabling conditions while highlighting systemic limitations in data available to characterize representativeness. Results emphasize how observed inequities interactively manifest through the compounding effects of minoritized social identity, inequitable economic conditions, and marginalizing medical experiences. Recommendations are discussed to more accurately quantify CCT participation inequities across underserved cancer populations and understand their underpinning mechanisms.
AI-Augmented Kidney Stone Composition Analysis with Auto-Release Improves Quality, Efficiency, Cost–Effectiveness, and Staff Satisfaction
Day, Patrick L. , Rokke, Denise, Schneider, Laura, Abbott, Jillian, Holmen, Brenda, Wieczorek, Mikolaj A. , Carter, Rickey E. , Bornhorst, Joshua A. , Jannetto, Paul J. , Johnson, Patrick, Carter, Rickey E , Bornhorst, Joshua , Day, Patrick , Schneider, Laura, Holmen, Brenda, Johnson, Patrick W. , Kunze, Katie L.

Mayo Clinic

The Journal of Applied Laboratory Medicine | December 19, 2024 | Volume: 10 | Issue: 2 | Pages: 305-314

10.1093/jalm/jfae146 | PMID 39700400 Get It

Abstract Background We sought to evaluate key performance indicators related to an internally developed and deployed artificial intelligence (AI)-augmented kidney stone composition test system for potential improvements in test quality, efficiency, cost-effectiveness, and staff satisfaction. Methods We compared quality, efficiency, staff satisfaction, and financial data from the 6 months after the AI-augmented laboratory test system was deployed (test period) with data from the same 6-month period in the previous year (control period) to determine if AI-augmentation improved key performance indicators of this laboratory test. Results In the 6 months following the deployment (test period) of the AI-augmented kidney stone composition test system, 44 830 kidney stones were analyzed. Of these, 92% of kidney stones were eligible for AI-assisted interpretation. Out of these AI-eligible stones, 45% were able to be auto-released by the AI-augmented test system without human secondary review. Furthermore, the new AI-augmented kidney stone test system resulted in an apparent 40% reduction in incorrect laboratory results. Additionally, the new AI-augmented test system improved laboratory efficiency by 20%, improved staff satisfaction, and reduced the average analysis cost per kidney stone by $0.23. Conclusions The AI-augmented test system improved test quality, efficiency, cost-effectiveness and staff satisfaction related to this kidney stone composition test.
International trends in biliary tract cancer–related mortality, 2000–2022: An observational study of the World Health Organization Mortality Database
Vu, Quynh Thi , Nishimura, Yoshito , Higashionna, Tsukasa , Maruo, Akinari, Harada, Keisaku , Takeda, Tatsuaki , Zamami, Yoshito , Koyama, Toshihiro , Harada, Ko , Higashionna, Tsukasa , Takeda, Tatsuaki , Hamano, Hirofumi , Hagiya, Hideharu , Koyama, Toshihiro , Nishimura, Yoshito , Ito, Hiroki , Hagiya, Hideharu

Mayo Clinic

Hepatology | December 19, 2024 | Volume: 82 | Issue: 3 | Pages: 626-637

10.1097/hep.0000000000001200 | PMID 39700462 Get It

Background and Aims: Biliary tract cancers (BTCs), including intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary cancer, exhibit poor prognosis. This study examined temporal trends in mortality due to BTCs and their major subtypes at international, regional, and national levels. Approach and Results: This observational study used the World Health Organization mortality database. Locally weighted regression (LOESS) was used to produce a smoothed curve of long-term international and regional BTC and major subtype-related mortality rates in 2000–2022 based on available data from countries. Trends in age-standardized mortality rates (ASRs) during 2013–2022 for individual countries were examined using joinpoint regression analysis. Internationally, LOESS-smoothed ASRs per 100,000 population due to BTCs were 2.8 (95% CI: 2.5–3.1) in 2000, and 2.7 (2.3–3.1) in 2022. LOESS-smoothed BTC-related ASRs were the highest in the Western Pacific region at 4.2 (1.8–6.6) in 2022, compared with those in the European and American regions at 2.6 (2.3–2.9) and 2.2 (1.8–2.6), respectively. Among major subtypes, LOESS-smoothed ASRs due to iCCA increased by 120.0%, those due to gallbladder cancer decreased by 45.5%, and those due to extrahepatic cholangiocarcinoma remained stable between 2000 and 2022. Disparities in BTC and major subtype-related ASR trends were observed between countries during 2013–2022, with iCCA-associated ASRs showing increasing trends in many countries. Conclusions: Although internationally estimated BTC-associated ASRs showed a stable trend over the last 2 decades, a large increase in estimated iCCA-associated ASRs necessitates developing effective screening for high-risk individuals and disease management strategies.
A Prospective, Randomized, Noninferiority Study to Evaluate the Safety and Effectiveness of Steerable Ureteroscopic Renal Evacuation Compared with Standard Ureteroscopy: 30-Day Results of the ASPIRE Study
Matlaga, Brian R., Johnson, Brett A. , Page, Jay, Wolf, J. Stuart, Preminger, Glenn M. , Jones, Loren, Sobol, Ilya , Stern, Karen , Cuellar, David, Cobb, Kaitlan, Barsky, Robert I, Medairos, Robert, Marguet, Charles G., Nimmagadda, Naren , Chi, Thomas , Johnson, Brett , Stern, Karen L , Mueller, Thomas J. , Jones, Loren, White, Mark, Levin, Michael

Mayo Clinic

Journal of Endourology | December 19, 2024 | Volume: 39 | Issue: 1 | Pages: 10-18

10.1089/end.2024.0602 | PMID 39699687 Get It

Purpose: We report the first multicenter, prospective, randomized noninferiority controlled trial of steerable ureteroscopic renal evacuation (SURE) for nephrolithiasis treatment. Materials and Methods: Candidates for laser lithotripsy ≥18 years with ≥1 renal stone ≥7 mm and 7–20 mm stone burden were randomized 1:1 SURE vs ureteroscopy (URS). SURE was performed using the CVAC Aspiration System, a novel steerable irrigation–aspiration catheter. The primary efficacy end point was noninferiority in stone-free rate (SFR) based on zero residual fragments (RFs) 30 days postprocedure on noncontrast computed tomography. Secondary end points were superiority tests, stone clearance (percent stone volume reduction), residual stone volume (RSV), SFR (no RF >2 mm), and SFR (no RF >4 mm) 30 days postprocedure. Results: Of the subjects, 123 were randomized and 101 qualified for efficacy analysis (SURE 46 vs URS 55). Despite randomization, baseline URS stone volume was higher (SURE 485.0 ± 432.5 mm 3 vs URS 713.3 ± 558.5 mm 3 ). The primary noninferiority end point was achieved (SURE SFR 48% vs URS SFR 49%, p = 0.027, −1.3% [90% confidence interval; −18%, 15%]). Stone clearance was significantly higher for SURE vs URS subjects (SURE 96.9 ± 5.6% vs URS 92.9 ± 11.6%, p = 0.036); RSV was significantly lower (SURE 14.3 ± 3 0.9 mm 3 vs URS 70.2 ± 144.9 mm 3 , p = 0.012). SURE stone clearance and RSV were independent of baseline stone volume, but for URS degraded with increasing baseline stone volume. Safety was comparable between groups. Conclusions: SFR for SURE subjects was noninferior compared with URS subjects; stone clearance and RSV were significantly better with SURE, independent of baseline stone volume.